discovery of glp-1 The transformative breakthroughs in research recognized by the 2024 Lasker~DeBakey award | Current Medicine History of glucagon-like peptide-1 receptor

Despite the ever-growing list of FDA-approved drugs, the success of anti-angiogenic therapy has so far been quite limited, only providing short-term relief from tumor growth before resistance occurs and typically resulting in modest survival benefits

Ben-Jonathan, N., LaPensee, C

Kaundal, R

The Role of a Building Block Glutamine is a nitrogen donor

Low HDL is a component of metabolic syndrome, a constellation of conditions that are associated with insulin resistance, elevated triglycerides and high blood pressure and too much fat around the waist

In May 2024 Novo Nordisk announced that an upcoming clinical trial would investigate GLP-1 drugs as a treatment for liver diseaseand explore their effects on alcohol consumption